Virtual Library

Start Your Search

Ramón Ropero



Author of

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-73 - Maintenance Treatment Using CimaVax EGF Vaccine. Experience of Single Institution (Now Available) (ID 1457)

      10:15 - 18:15  |  Author(s): Ramón Ropero

      • Abstract
      • Slides

      Background

      In Cuba the lung cancer represented the first cause of mortality for both sex. Approximately 75-85% of non small cell lung cancer (NSCLC) overexpresses the Epidermal grow factor receptor (EGFR) and its ligands.

      Overexpression of EGFR has been implicated in the process of malignant transformation by promoting cell proliferation, cell survival and motility. EGFR is a well-validated target for patients with NSCLC. CIMAvax-EGF is a therapeutic cancer vaccine composes of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF–EGFR interaction.

      Method

      To characterize patients with non-small cell lung cancer treated with CIMAvax-EGF vaccine in maintenance regimen in the real world. Patients Selection: Patients diagnosed from stage IIIB and IV NSCLC at the National Institute of Oncology and Radiobiology in the period from January 2015 to June 2017 and who achieved objective response or stable disease at the end of first line therapy (chemotherapy alone or concomitant chemoradiotherapy).Treatment schedule: After finished first-line treatment, patients who achieved objective response or stabilization start vaccine maintenance regimen as previous described [Rodríguez PC, 2016].

      Result

      A total of 106 patients were treated, 52.8% of the patients were 65 or more years old, 58.5% were male and 48.5% female. The performance status was 1 in 77.4%. 62.3% of the patients were diagnosed from Adenocarcinoma. After started vaccination the 36.8% and 19.8% of patients, kept the objective response or stable disease, at 6 and 12 months respectively. The treatment was well tolerated, more frequents adverse events were pain (27,3 %) and indurations (7.3%) in the site of injection as well as local erithema (10,9%). The median overall survival was 14.6 months IC95% (10.6 -18.6). The overall survival rates were 82.1%, 57.2% and 37.6% at 6, 12 y 24 months, respectively. The median OS for patients less than 65 years old was 16,7 months IC 95% (2.2- 31.1) and for patients with ECOG 0 was 29 months IC 95% (10.4-47.5). The median progression free survival was 8.16 months IC 95%(4.9- 11.3). Progression free survival rates were 55,4%, 36,4% and 19,1% at 6, 12 and 24 months.

      Conclusion

      Maintenance treatment using CIMAvax-EGF vaccine shown excellent safety profile. Median PFS and OS were higher than previously reported in phase III clinical trial. Patients less than 65 years old and with ECOG=0 achieved the better overall survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.